Suzhou, China-based Ascentage Pharma Group International, a biopharmaceutical company focused on developing therapies for hematological malignancies, has priced its initial public offering of 7.33 million American depositary shares or ADSs at $17.25 per ADS.
The ADSs will begin trading on the Nasdaq Global Market on January 24, 2025, under the ticker symbol "AAPGV," with regular trading expected to commence on January 27, 2025, under the ticker symbol "AAPG."
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com